(12) **Translation of European patent specification**

(11) **NO/EP 3484865 B1**

(19) NO

NORWAY

(51) Int Cl.

C07D 401/04 (2006.01) ***A61K 9/48 (2006.01)*** ***A61K 31/502 (2006.01)***
A61K 9/20 (2006.01) ***A61K 31/4725 (2006.01)***

Norwegian Industrial Property Office

(45)	Translation Published	2022.12.05
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.09.14
(86)	European Application Nr.	17828375.0
(86)	European Filing Date	2017.07.12
(87)	The European Application's Publication Date	2019.05.22
(30)	Priority	2016.07.14, US, 201662362493 P 2016.10.21, US, 201662411338 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
	Designated Extension States:	BA; ME
(73)	Proprietor	Crinetics Pharmaceuticals, Inc., 10222 Barnes Canyon Road, Building No. 2, San Diego, CA 92121, USA
(72)	Inventor	ZHAO, Jian, 10222 Barnes Canyon Road Building 2, San Diego, California 92121, USA HAN, Sangdon, 10222 Barnes Canyon Road Building 2, San Diego, California 92121, USA KIM, Sun Hee, 10222 Barnes Canyon Road Building 2, San Diego, California 92121, USA WANG, Shimiao, 10222 Barnes Canyon Road Building 2, San Diego, California 92121, USA ZHU, Yunfei, 10222 Barnes Canyon Road Building 2, San Diego, California 92121, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **SOMATOSTATIN MODULATORS AND USES THEREOF**

(56) References Cited:

KR-A- 20160 062 023
EP-A1- 2 871 179
US-A1- 2015 232 478
US-A1- 2003 153 553
WO-A2-2008/051272
WO-A1-2010/041054
Scott E. Wolkenberg ET AL: "Design, Synthesis, and Evaluation of Novel 3,6-Diaryl-4-aminoalkoxyquinolines as Selective Agonists of Somatostatin Receptor Subtype 2", Journal of Medicinal Chemistry, vol. 54, no. 7, 14 April 2011 (2011-04-14) , pages 2351-2358, XP055569581, US ISSN: 0022-2623, DOI: 10.1021/jm101501b

Patentkrav

1. Forbindelse som har følgende struktur, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav:



hvori:

hver R^a er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-CH_2OH$ eller $-CH_2CH_2OH$;

hver R^b er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$ eller $-OCF_3$;

m er 1 eller 2; n er 0, 1 eller 2;

R^B er  ,  eller  ;

hver R^c er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH(CH_3)_2$, $-CH(CH_3)(CH_2CH_3)$, $-C(CH_3)_3$, $-CH_2OH$, $-CH_2CN$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCH_2CH_3$, $-OCF_3$, $-CO_2H$, $-CO_2CH_3$, $-CO_2CH_2CH_3$, $-CH_2CO_2H$, $-CH_2CO_2CH_3$, $-CH_2CO_2CH_2CH_3$, $-C(=O)NH_2$, $-C(=O)NHCH_3$, $-C(=O)NHOCH_3$, $-C(=O)N(CH_3)_2$, $-SO_2N(CH_3)_2$, $-C(=NOCH_3)H$, $-CH_2C(=O)NH_2$, $-CH_2C(=O)NHCH_3$, $-CH_2C(=O)N(CH_3)_2$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-NHCO_2CH_3$, $-NHSO_2CH_3$, $-CH_2NH_2$, $-CH_2NHCH_3$, $-CH_2N(CH_3)_2$, $-CH(CF_3)NH_2$, azetidinyl eller pyrrolidinyl;

hver R^d er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH(CH_3)_2$, $-CH(CH_3)(CH_2CH_3)$, $-C(CH_3)_3$, $-CH_2OH$, $-CH_2CN$, $-CH_2F$, $-CHF_2$, $-CF_3$, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, -CN, -OH, $-OCH_3$, $-OCH_2CH_3$, $-OCF_3$, $-OCH_2OCH_3$, $-OCH_2OCH_2CH_3$, $-OCH_2CH_2OH$, $-C(=O)NHOCH_3$, $-C(=NOH)H$, $-C(=NOCH_3)H$, $-CH_2C(=O)NH_2$, $-NH_2$, $-NHCO_2CH_3$, $-NHSO_2CH_3$, $-NH(C=O)NHCH_3$, $-NH(C=O)NHOCH_3$ eller $-CH(CF_3)NH_2$;

eller dersom en R^c og en R^d er på tilstøtende atomer av R^B, blir de tilstøtende R^c- og R^d-gruppene tatt sammen med de mellomliggende atomene som de er festet til for å danne en 5- eller 6-leddet monosyklisk heterosyklisk ring;

p er 1 eller 2; q er 0, 1 eller 2;

X er CR^f eller N;

Y er CR^f eller N;

Z er CR^f eller N;

R^e er hydrogen, F, Cl, Br, $-CH_3$, $-CH_2CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCH_2CH_3$ eller $-OCF_3$;

hver R^f er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCH_2CH_3$ eller $-OCF_3$;

R^1 er hydrogen;

R^2 er hydrogen, metyl, etyl, 2-fluoretyl, 2-hydroksyetyl, 2-metoksyetyl, n-propyl, i-propyl, syklopropyl, 3-fluorpropyl, 3-metoksypropyl, n-butyl, i-butyl, sek-butyl, syklobutyl, tert-butyl eller oksetanyl;

R^5 er hydrogen, F, Cl, Br, -OH, $-OCH_3$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-OCH_2CH_3$, $-OCF_3$, $-CH_3$, $-CH_2CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, $-C(=O)OCH_3$, $-C(=O)NH_2$, $-C(=O)NHCH_3$ eller $-C(=O)N(CH_3)_2$;

eller R^2 og R^5 blir tatt sammen med de mellomliggende atomene som de er festet til for å danne et azetidinyl, pyrrolidinyl, piperidinyl, morfolinyl, tiomorfolinyl, piperazinyl eller azepanyl.

2. Forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav, hvori:

hver R^a er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-CH_2OH$ eller $-CH_2CH_2OH$;

hver R^b er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$ eller $-OCF_3$;

hver R^c er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-NH_2$, $-C(=O)NH_2$, $-C(=NOCH_3)H$, $-SO_2N(CH_3)_2$, azetidinyl eller pyrrolidinyl;

hver R^d er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-OCH_2OCH_3$, $-CH_2OH$, $-OCH_2CH_2OH$, $-C(=O)NHOCH_3$, $-NH_2$, $-NHCO_2CH_3$, $-NH(C=O)NHOCH_3$ eller $-CH_2C(=O)NH_2$;

eller hvis en R^c og en R^d er på tilstøtende atomer av R^B, blir de tilstøtende R^c- og R^d-gruppene tatt sammen med de mellomliggende atomene som de er festet til for å danne 5-leddet monosyklisk heterosyklisk ring.

3. Forbindelsen ifølge krav 1 eller krav 2, hvori forbindelsen har følgende struktur, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav:



.

4. Forbindelsen ifølge et hvilket som helst av kravene 1 til 3, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav, hvori:

hver R^a er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-CH_2OH$ eller $-CH_2CH_2OH$;

hver R^b er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$ eller $-OCF_3$;

hver R^c er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-NH_2$, $-C(=O)NH_2$, $-C(=NOCH_3)H$, $-SO_2N(CH_3)_2$, azetidinyl eller pyrrolidinyl;

hver R^d er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-OCH_2OCH_3$, $-CH_2OH$, $-OCH_2CH_2OH$, $-C(=O)NHOCH_3$, $-NH_2$, $-NHCO_2CH_3$, $-NH(C=O)NHOCH_3$ eller $-CH_2C(=O)NH_2$;

R^e er hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$ eller $-OCF_3$;

hver R^f er hydrogen;

R^1 er hydrogen;

R^2 er hydrogen;

R^5 er hydrogen, F, Cl, Br, -OH, $-OCH_3$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-OCH_2CH_3$, $-OCF_3$, $-CH_3$, $-CH_2CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, $-C(=O)OCH_3$, $-C(=O)NH_2$, $-C(=O)NHCH_3$ eller $-C(=O)N(CH_3)_2$;

eller R^2 og R^5 blir tatt sammen med de mellomliggende atomene som de er festet til for å danne et piperidinyl, morfolinyl, tiomorfolinyl eller piperazinyl.

5. Forbindelsen ifølge et hvilket som helst av kravene 1 til 4, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav, hvori:

hver R^a er uavhengig hydrogen, F, Cl, $-CH_3$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-CH_2OH$ eller $-CH_2CH_2OH$

hver R^b er uavhengig hydrogen, F, Cl, $-CH_3$, $-CF_3$, -CN, -OH, $-OCH_3$ eller $-OCF_3$;

hver R^c er uavhengig hydrogen, F, Cl, $-CH_3$, $-CF_3$, -CN, -OH, $-OCH_3$ eller $-OCF_3$;

hver R^d er uavhengig hydrogen, F, Cl, $-CH_3$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$ eller $-NH_2$;

X er CR^f; Y er CR^f; og Z er CR^f;

eller X er N; Y er CR^f; og Z er CR^f;

eller X er CR^f; Y er N; og Z er CR^f;

eller X er CR^f; Y er CR^f; og Z er N;

R^e er hydrogen, F eller Cl;

hver R^f er hydrogen;

R^1 er hydrogen;

R^2 er hydrogen;

R^5 er hydrogen;

eller R^2 og R^5 blir tatt sammen med de mellomliggende atomene som de er festet til for å danne et morfolinyl.

6. Forbindelsen ifølge et hvilket som helst av kravene 1 til 3, hvori forbindelsen har følgende struktur av formel (AVb), eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav:



Formel (AVb)

hvori:

R^B er  ;

R^1 er hydrogen;

R^2 er hydrogen, metyl, etyl, 2-fluoretyl, 2-hydroksyetyl, 2-metoksyetyl, n-propyl, i-propyl, syklopropyl, 3-fluorpropyl, 3-metoksypropyl, n-butyl, i-butyl, sek-butyl, syklobutyl, tert-butyl eller oksetanyl;

R^5 er hydrogen, F, Cl, Br, -OH, $-OCH_3$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-OCH_2CH_3$, $-OCF_3$, $-CH_3$, $-CH_2CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, $-C(=O)OCH_3$, $-C(=O)NH_2$, $-C(=O)NHCH_3$ eller $-C(=O)N(CH_3)_2$;

eller R^2 og R^5 blir tatt sammen med de mellomliggende atomene som de er festet til for å danne et azetidinyl, pyrrolidinyl, piperidinyl, morfolinyl, tiomorfolinyl, piperazinyl eller azepanyl.

7. Forbindelsen ifølge krav 6, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav, hvori:

R^a er hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-CH_2OH$ eller $-CH_2CH_2OH$;

R^b er hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$ eller $-OCF_3$;

hver R^c er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-NH_2$, $-C(=O)NH_2$, $-C(=NOCH_3)H$, $-SO_2N(CH_3)_2$, azetidinyl eller pyrrolidinyl;

hver R^d er uavhengig hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$, $-OCF_3$, $-OCH_2OCH_3$, $-CH_2OH$, $-OCH_2CH_2OH$, $-C(=O)NHOCH_3$, $-NH_2$, $-NHCO_2CH_3$, $-NH(C=O)NHOCH_3$ eller $-CH_2C(=O)NH_2$;

R^e er hydrogen, F, Cl, Br, $-CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, -OH, $-OCH_3$ eller $-OCF_3$;

R^1 er hydrogen;

R^2 er hydrogen;

R^5 er hydrogen, F, Cl, Br, -OH, $-OCH_3$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-OCH_2CH_3$, $-OCF_3$, $-CH_3$, $-CH_2CH_3$, $-CH_2F$, $-CHF_2$, $-CF_3$, -CN, $-C(=O)OCH_3$, $-C(=O)NH_2$, $-C(=O)NHCH_3$ eller $-C(=O)N(CH_3)_2$;

eller R^2 og R^5 blir tatt sammen med de mellomliggende atomene som de er festet til for å danne et piperidinyl, morfolinyl, tiomorfolinyl eller piperazinyl.

8. Forbindelsen ifølge krav 6 eller krav 7, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav, hvori:

R^a er hydrogen, F, Cl, $-CH_3$, $-CF_3$, -CN, -OH, $-CH_2OH$, $-CH_2CH_2OH$, $-OCH_3$ eller $-OCF_3$;

R^b er hydrogen, F, Cl, $-CH_3$, $-CF_3$, -CN, -OH, $-OCH_3$ eller $-OCF_3$;

hver R^c er uavhengig hydrogen, F, Cl, $-CH_3$, $-CF_3$, -CN, -OH, $-NH_2$, $-OCH_3$, $-OCF_3$, $-CONH_2$ eller $-C(=NOCH_3)H$;

hver R^d er uavhengig hydrogen, F, Cl, $-CH_3$, $-CF_3$, -CN, -OH, $-NH_2$, $-OCH_3$ eller $-OCF_3$;

R^1 er hydrogen;

R^2 er hydrogen;

R^5 er hydrogen;

eller R^2 og R^5 blir tatt sammen med de mellomliggende atomene som de er festet til for å danne et morfolinyl.

9. Forbindelsen ifølge krav 1, hvori forbindelsen er:

1-1: 3-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3,5-dimetylfenyl)cinnolin-6-yl]-5-fluorbenzamid;

1-2: 3-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3,5-dimetylfenyl)cinnolin-6-yl]-2-hydroksybenzonitril;

1-4: 3-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3-fluor-5-metylfenyl)cinnolin-6-yl]-5-fluorbenzamid;

1-5: 3-{4-[trans-4-amino-3-fluorpiperidin-1-yl]-7-klor-3-(3-fluor-5-metylfenyl)cinnolin-6-yl}-5-fluorbenzamid;

1-6: 3-{4-[cis-4-amino-3-fluorpiperidin-1-yl]-7-klor-3-(3-fluor-5-metylfenyl)cinnolin-6-yl}-5-fluorbenzamid;

1-7: 3-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3-fluor-5-metylfenyl)cinnolin-6-yl]-2-hydroksybenzonitril;

1-8: 5-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3-fluor-5-metylfenyl)cinnolin-6-yl]-2,3-dihydro-1H-1,3-benzodiazol-2-on;

1-9: 4-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3-fluor-5-metylfenyl)cinnolin-6-yl]-2,3-dihydro-1H-1,3-benzodiazol-2-on;

1-10: 3-{4-[trans-4-amino-3-metoksypiperidin-1-y1]-7-klor-3-(3-fluor-5-metylfenyl)cinnolin-6-yl}-5-fluorbenzamid;

1-11: 3-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3,5-diklorfenyl)cinnolin-6-yl]-2-hydroksybenzonitril;

1-12: 3-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3-klor-5-metylfenyl)cinnolin-6-yl]-5-fluor-2-hydroksybenzonitril;

1-13: 3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)cinnolin-6-yl]-5-fluorbenzamid;

1-14: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)cinnolin-6-yl]-5-fluorbenzamid;

1-16: 5-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)cinnolin-6-yl]-2,3-dihydro-1H-1,3-benzodiazol-2-on;

1-17: 3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)cinnolin-6-yl]-2-hydroksybenzonitril;

1-18: 3-[4-(4-aminopiperidin-1-yl)-3-(3-klor-5-metylfenyl)cinnolin-6-yl]-2-hydroksybenzonitril;

1-19: 3-[4-(4-aminopiperidin-1-yl)-3-(3-klor-5-fluorfenyl)cinnolin-6-yl]-2-hydroksybenzonitril;

1-20: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)cinnolin-6-yl]-2-hydroksybenzonitril;

1-21: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-diklorfenyl)cinnolin-6-yl]-2-hydroksybenzonitril;

1-22: 3-[4-(4-aminopiperidin-1-yl)-3-(3-klor-5-metylfenyl)cinnolin-6-yl]-5-fluor-2-hydroksybenzonitril;

1-23: 6-[4-(4-aminopiperidin-1-yl)-3-(3-klor-5-metylfenyl)cinnolin-6-yl]-4-fluor-2,3-dihydro-1H-1,3-benzodiazol-2-on;

1-24: 4-[4-(4-aminopiperidin-1-yl)-3-(3-klor-5-metylfenyl)cinnolin-6-yl]-6-fluor-2,3-dihydro-1H-1,3-benzodiazol-2-on;

1-25: 3-[7-klor-3-(3-fluor-5-metylfenyl)-4-{4-[(2-fluoretyl)amino]piperidin-1-yl}cinnolin-6-yl]-5-fluorbenzamid;

1-26: 3-{4-[trans-4-amino-3-hydroksypiperidin-1-yl]-7-klor-3-(3-fluor-5-metylfenyl)cinnolin-6-yl}-5-fluorbenzamid;

1-27: 3-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3,5-diklorfenyl)cinnolin-6-yl]-5-fluor-2-hydroksybenzonitril;

1-28: 6-[4-(4-aminopiperidin-1-yl)-3-(3,5-diklorfenyl)cinnolin-6-yl]-4-fluor-2,3-dihydro-1H-1,3-benzodiazol-2-on;

1-29: 2-[4-(4-aminopiperidin-1-yl)-3-(3-klor-5-metylfenyl)cinnolin-6-yl]-6-fluorfenol;

1-30: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-diklorfenyl)cinnolin-6-yl]-5-fluorbenzamid;

1-31: 3-[3-(3,5-diklorfenyl)-4-{4-[(oksetan-3-yl)amino]piperidin-1-yl}cinnolin-6-yl]-5-fluorbenzamid;

1-33: 3-[3-(3,5-diklorfenyl)-4-{4-[(2-fluoretyl)amino]piperidin-1-yl}cinnolin-6-yl]-5-fluorbenzamid;

1-35: 3-[7-klor-3-(3-klor-5-metylfenyl)-4-{4-[(2-fluoretyl)amino]piperidin-1-yl}cinnolin-6-yl]-5-fluorbenzamid;

1-36: 3-[7-klor-3-(3-klor-5-metylfenyl)-4-{4-[(2-fluoretyl)amino]piperidin-1-yl}cinnolin-6-yl]-5-fluor-2-hydroksybenzonitril;

1-38: 3-[7-klor-3-(3-klor-5-metylfenyl)-4-{4-[(oksetan-3-yl)amino]piperidin-1-yl}cinnolin-6-yl]-5-fluorbenzamid;

1-39: 3-[7-klor-3-(3-klor-5-metylfenyl)-4-{4-[(oksetan-3-yl)amino]piperidin-1-yl}cinnolin-6-yl]-5-fluor-2-hydroksybenzonitril;

1-40: 3-[3-(3-klor-5-metylfenyl)-4-{4-[(oksetan-3-yl)amino]piperidin-1-yl}cinnolin-6-yl]-5-fluor-2-hydroksybenzonitril;

1-41: 3-{4-[trans-4-amino-3-fluorpiperidin-1-yl]-7-klor-3-(3-klor-5-metylfenyl)cinnolin-6-yl}-5-fluorbenzamid;

1-42: 6-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3-klor-5-metylfenyl)cinnolin-6-yl]pyridin-2-karboksamid;

1-43: 6-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3-klor-5-metylfenyl)cinnolin-6-yl]-5-klorpyridin-2-karboksamid;

1-44: 2-[4-(4-aminopiperidin-1-yl)-7-klor-3-(3-klor-5-metylfenyl)cinnolin-6-yl]pyridin-4-karboksamid;

1-45: 2-[4-(4-aminopiperidin-1-yl)-3-(3-klor-5-metylfenyl)cinnolin-6-yl]-6-fluor-3-metylfenol;

1-48: 3-{4-[cis-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-klor-5-metylfenyl)cinnolin-6-yl}-5-fluorbenzamid;

1-49: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-klor-5-metylfenyl)cinnolin-6-yl}-5-fluorbenzamid;

1-51: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-diklorfenyl)cinnolin-6-yl}-2-hydroksybenzonitril;

1-52: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-klor-5-metylfenyl)cinnolin-6-yl}-2-hydroksybenzonitril;

1-53: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metylfenyl)cinnolin-6-yl}-2-hydroksybenzonitril;

1-54: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)cinnolin-6-yl}-2-hydroksybenzonitril;

1-55: 5-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)cinnolin-6-yl}-4-aminopyridin-3-karbonitril;

1-56: 5-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metylfenyl)cinnolin-6-yl}-4-aminopyridin-3-karbonitril;

1-57: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)cinnolin-6-yl}-3-aminopyridin-4-karbonitril;

1-58: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metylfenyl)cinnolin-6-yl}-3-aminopyridin-4-karbonitril;

eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav.

10. Forbindelsen ifølge krav 1, hvori forbindelsen er:

2-1: 3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-2-hydroksybenzonitril;

2-2: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-2-hydroksybenzonitril;

2-3: 3-{4-[trans-4-amino-3-metoksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-hydroksybenzonitril;

2-4: 3-{4-[trans-4-amino-3-metoksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}benzonitril;

2-5: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]benzonitril;

2-6: 2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]fenol;

2-7: 6-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]pyridin-2-karboksamid;

2-8: 4-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-2,3-dihydro-1H-1,3-benzodiazol-2-on;

2-9: 5-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-2,3-dihydro-1H-1,3-benzodiazol-2-on;

2-10: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-5-fluor-2-hydroksybenzonitril;

2-16: 3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-fluor-2-hydroksybenzonitril;

2-19: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-hydroksybenzonitril;

2-20: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl }-2-hydroksybenzonitril;

2-58: 3-{4-[cis-4-amino-3-hydroksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-(metoksymetoksy)benzonitril;

2-59: 3-{4-[(3R,4R)-4-amino-3-fluorpiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-hydroksybenzonitril;

2-60: 3-{4-[cis-4-amino-3-hydroksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-hydroksybenzonitril;

2-61: 3-{4-[(3S,4R)-4-amino-3-metoksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-hydroksybenzonitril;

2-62: 3-{4-[(3R,4S)-4-amino-3-metoksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-(metoksymetoksy)benzonitril;

2-63: 3-{4-[cis-4-amino-3-hydroksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-5-fluor-2-hydroksybenzonitril;

2-65: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-2-(2-hydroksyethoksy)benzonitril;

2-66: 3-{4-[(3R,4S)-4-amino-3-metoksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-hydroksybenzonitril;

2-75: 5-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-6-(azetidin-1-yl)pyridin-3-karbonitril;

2-76: 5-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-6-(azetidin-1-yl)pyridin-3-karboksamid;

2-77: 2-amino-3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]benzonitril;

2-78: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-2-(metoksymetoksy)benzonitril;

2-80: 6-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-fluor-2,3-dihydro-1H-1,3-benzodiazol-2-on;

2-81: 2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-6-[-(metoksyimino)metyl]fenol;

2-83: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4,6-difluorfenyl}karbamat;

2-84: 3-{4-[trans-4-amino-3-metoksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-(metoksymetoksy)benzonitril;

2-85: 6-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}pyridin-2-karboksamid;

2-86: N-{2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4,6-difluorfenyl}metansulfonamid;

2-92: trans-4-amino-1-[6-(3-cyano-2-hydroksyfenyl)-3-(3,5-difluorfenyl)kinolin-4-yl]piperidin-3-karbonitril;

2-94: cis-4-amino-1-[6-(3-cyano-2-hydroksyfenyl)-3-(3,5-difluorfenyl)kinolin-4-yl]piperidin-3-karbonitril;

2-99: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4,5-difluor-2-hydroksybenzonitril;

2-100: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4,5-difluor-2-hydroksybenzonitril;

2-102: 3-{4-[trans-4-amino-3-metoksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4,5-difluor-2-hydroksybenzonitril;

2-103: 3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-4,5-difluor-2-hydroksybenzonitril;

2-104: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl}-4,5-difluor-2-hydroksybenzonitril;

2-106: 3-{4-[trans-4-amino-3-metoksypiperidin-1-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl}-4,5-difluor-2-hydroksybenzonitril;

2-107: 3-{4-[cis-4-amino-3-hydroksypiperidin-1-yl]-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl}-4,5-difluor-2-hydroksybenzonitril;

2-108: 2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4,6-difluor-3-metylfenol;

2-109: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4,6-difluor-3-metylfenol;

2-111: 2-{4-[trans-4-amino-3-metoksypiperidin-1-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4,6-difluor-3-metylfenol;

2-112: 2-{4-[trans-4-amino-3-metoksypiperidin-1-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl}-4,6-difluor-3-metylfenol;

2-113: cis-4-amino-1-[6-(3,5-difluor-2-hydroksy-6-metylfenyl)-3-(3-fluor-5-metoksyfenyl)kinolin-4-yl]piperidin-3-ol;

2-114: 2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4-fluor-6-[(metoksyimino)metyl]fenol;

2-115: 2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-6-[(metoksyimino)metyl]fenol;

2-116: 2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-4-fluor-6-[(metoksyimino)metyl]fenol;

2-117: 2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-3,4-difluor-6-[(metoksyimino)metyl]fenol;

2-118: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl}-4-fluor-6-[(1E)-(metoksyimino)metyl]fenol;

2-119: trans-4-amino-1-[6-(3-cyano-5,6-difluor-2-hydroksyfenyl)-3-(3,5-difluorfenyl)kinolin-4-yl]piperidin-3-karbonitril;

2-120: cis-4-amino-1-[6-(3-cyano-5,6-difluor-2-hydroksyfenyl)-3-(3,5-difluorfenyl)kinolin-4-yl]piperidin-3-karbonitril;

2-121: trans-4-amino-1-[6-(3-cyano-5,6-difluor-2-hydroksyfenyl)-3-(3-fluor-5-metylfenyl)kinolin-4-yl]piperidin-3-karbonitril;

2-122: cis-4-amino-1-[6-(3-cyano-5,6-difluor-2-hydroksyfenyl)-3-(3-fluor-5-metylfenyl)kinolin-4-yl]piperidin-3-karbonitril;

2-123: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-3,4,6-trifluorfenyl}karbamat;

2-124: metyl-N-{3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-5-fluorpyridin-4-yl}karbamat;

2-125: metyl-N-{3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-5-cyanopyridin-4-yl}karbamat;

2-126: 1-[3-(3,5-difluorfenyl)-6-{3-fluor-2-[(hydroksyimino)metyl]fenyl}kinolin-4-yl]piperidin-4-amin;

2-127: 1-(6-{3-klor-2-[(hydroksyimino)metyl]fenyl}-3-(3,5-difluorfenyl)kinolin-4-yl)piperidin-4-amin;

2-128: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-2-[(hydroksyimino)metyl]benzonitril;

2-129: 1-[3-(3,5-difluorfenyl)-6-{3-fluor-2-[(metoksyimino)metyl]fenyl}kinolin-4-yl]piperidin-4-amin;

2-130: 1-(6-{3-klor-2-[(metoksyimino)metyl]fenyl}-3-(3,5-difluorfenyl)kinolin-4-yl)piperidin-4-amin;

2-131: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-2-[(1E)-(metoksyimino)metyl]benzonitril;

2-132: 1-{6-[3-(1-amino-2,2,2-trifluoretyl)fenyl]-3-(3,5-difluorfenyl)kinolin-4-yl}piperidin-4-amin;

2-133: 1-{6-[2-(1-amino-2,2,2-trifluoretyl)-3-fluorfenyl]-3-(3,5-difluorfenyl)kinolin-4-yl}piperidin-4-amin;

2-134: 2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-6-klor-3,4-difluorfenol;

2-135: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-6-klor-3,4-difluorfenol;

2-136: 2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-6-klor-4-fluorfenol;

2-137: 2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-6-klorfenol;

2-138: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-6-klorfenol;

2-139: 1-{2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4,6-difluorfenyl}-3-metoksyurea;

2-140: 1-(2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4,6-difluorfenyl)-3-metoksyurea;

2-141: 6-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4-klor-2,3-dihydro-1H-1,3-benzodiazol-2-on;

2-142: 5-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-2,3-dihydro-1,3-benzoksazol-2-on;

2-143: metyl-trans-4-amino-1-[6-(3-cyano-2-hydroksyfenyl)-3-(3,5-difluorfenyl)kinolin-4-yl]piperidin-3-karboksylat;

2-144: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-6-fluorfenol;

2-146: trans-4-amino-1-[6-(3-cyano-2-hydroksyfenyl)-3-(3,5-difluorfenyl)kinolin-4-yl]piperidin-3-karboksamid;

2-147: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-5-klor-4-fluor-2-hydroksybenzonitril;

2-148: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-6-cyanofenyl}karbamat;

2-149: trans-4-amino-1-[6-(3-cyano-2-hydroksyfenyl)-3-(3,5-difluorfenyl)kinolin-4-yl]-N-metylpiperidin-3-karboksamid;

2-150: 2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-3,4,6-trifluorfenol;

2-151: trans-4-amino-1-[6-(3-cyano-2-hydroksyfenyl)-3-(3,5-difluorfenyl)kinolin-4-yl]-N,N-dimetylpiperidin-3-karboksamid;

2-152: 1-[3-(3,5-difluorfenyl)-6-{5-fluor-4-[(hydroksyimino)metyl]pyridin-3-yl}kinolin-4-yl]piperidin-4-amin;

2-153: N-[(2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-6-fluorfenyl)metyliden]hydroksylamin;

2-154: N-[(2-{4-[(trans)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4,6-difluorfenyl)metyliden]hydroksylamin;

2-155: N-[(2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl}-6-fluorfenyl)metyliden]hydroksylamin;

2-156: 4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-[3-fluor-2-(1H-imidazol-2-yl)fenyl]-3-(3-fluor-5-metoksyfenyl)kinolin;

2-157: 4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-[3-fluor-2-(1H-imidazol-5-yl)fenyl]-3-(3-fluor-5-metoksyfenyl)kinolin;

2-158: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl}-4,5-difluor-2-hydroksybenzonitril;

2-159: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl}-4,5-difluor-2-hydroksybenzonitril;

2-160: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl}-3,4,6-trifluorfenol;

2-161: 1-[3-(3-fluor-5-metoksyfenyl)-6-(2,3,5-trifluor-6-hydroksyfenyl)kinolin-4-yl]piperidin-4-ol;

2-162: 1-{3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-5-hydroksypyridin-4-yl}-3-metoksyurea;

2-163: 1-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl]-6-klorfenyl}-3-metoksyurea;

2-164: 1-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl]-4,6-difluorfenyl}-3-metoksyurea;

2-165: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl]-4,6-difluorfenyl}karbamat;

2-166: 1-(6-{3-fluor-2-[(hydroksyimino)metyl]fenyl}-3-(3-fluor-5-metoksyfenyl)kinolin-4-yl)piperidin-4-amin;

2-167: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl]-6-cyanofenyl}karbamat;

2-168: 1-(6-{5-fluor-4-[(hydroksyimino)metyl]pyridin-3-yl}-3-(3-fluor-5-metylfenyl)kinolin-4-yl)piperidin-4-amin;

2-169: 3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-fluorpyridin-4-amin;

2-170: metyl-(trans)-4-amino-1-[6-(3-cyano-2-hydroksyfenyl)-3-(3,5-difluorfenyl)kinolin-4-yl]piperidin-3-karboksylat;

2-171: metyl-N-{3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-fluorpyridin-4-yl}karbamat;

2-172: 1-{3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-fluorpyridin-4-yl}-3-metoksyurea;

2-173: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl]-6-fluorfenyl}karbamat;

2-174: 1-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metoksyfenyl)kinolin-6-yl]-6-fluorfenyl}-3-metoksyurea;

2-176: 1-(6-{5-fluor-4-[(hydroksyimino)metyl]pyridin-3-yl}-3-[3-fluor-5-(trifluormetyl)fenyl]kinolin-4-yl)piperidin-4-amin;

2-177: 4-amino-5-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]pyridin-3-karbonitril;

2-178: 3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-fluorpyridin-2-amin;

2-179: 2-amino-3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4,5-difluorbenzonitril;

2-180: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-6-cyano-3,4-difluorfenyl}karbamat;

2-181: 3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-klorpyridin-4-amin;

2-182: metyl-N-{3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-fluorpyridin-2-yl}karbamat;

2-183: 1-{3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-fluorpyridin-2-yl}-3-metoksyurea;

2-184: metyl-N-{3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-klorpyridin-4-yl}karbamat;

2-185: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4-cyanofenyl}karbamat;

2-186: 1-{3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-klorpyridin-4-yl}-3-metoksyurea;

2-187: 4-amino-5-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]pyridin-3-karbonitril;

2-189: 1-{2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4-cyanofenyl}-3-metoksyurea;

2-190: 3-{4-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-hydroksybenzonitril;

2-192: 1-(6-{5-klor-4-[(hydroksyimino)metyl]pyridin-3-yl}-3-(3,5-difluorfenyl)kinolin-4-yl)piperidin-4-amin;

2-193: 3-{4-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-2-hydroksybenzonitril;

2-194: 3-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-5-fluor-2-(metoksymetoksy)benzonitril;

2-195: 1-[3-(3,5-difluorfenyl)-6-{3-[(hydroksyimino)metyl]pyridin-2-yl}kinolin-4-yl]piperidin-4-amin;

2-196: 1-[3-(3,5-difluorfenyl)-6-{2-[(hydroksyimino)metyl]pyridin-3-yl}kinolin-4-yl]piperidin-4-amin;

2-197: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-4,6-difluorfenyl}karbamat;

2-200: 1-[3-(3,5-difluorfenyl)-6-{6-[(hydroksyimino)metyl]pyridin-2-yl}kinolin-4-yl]piperidin-4-amin;

2-202: 1-[3-(3,5-difluorfenyl)-6-{3-fluor-2-[(hydroksyimino)metyl]-6-metylfenyl}kinolin-4-yl]piperidin-4-amin;

2-205: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-6-cyano-3,4-difluorfenyl}karbamat;

2-207: 1-(2-{4-[cis-4-amino-3-metoksypiperidin-1-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl}-4,6-difluorfenyl)-3-metoksyurea;

2-208: 1-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-6-cyano-3,4-difluorfenyl}-3-metylurea;

2-209: metyl-N-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-6-fluorfenyl}karbamat;

2-213: 4-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-2-[(metoksyimino)metyl]fenol;

2-215: 1-{3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-4-metylpyridin-2-yl}-3-metoksyurea;

2-217: trans-1-(6-{3-fluor-2-[(hydroksyimino)metyl]fenyl}-3-(3-fluor-5-metylfenyl)kinolin-4-yl)-3-metoksypiperidin-4-amin;

2-218: metyl-N-(2-{4-[trans-4-amino-3-metoksypiperidin-1-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl}-6-cyanofenyl)karbamat;

2-219: cis-3-{4-[4-amino-3-hydroksypiperidin-1-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl}-5-fluor-2-hydroksybenzonitril;

2-221: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl}-6-[(metoksyimino)metyl]fenol;

2-222: 1-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-4-cyanofenyl}-3-metoksyurea;

2-223: 1-{3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-5-fluorfenyl}-3-metoksyurea;

2-226: 1-{3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]pyridin-2-yl}-3-metoksyurea;

2-227: cis-4-amino-1-(6-{3-fluor-2-[(hydroksyimino)metyl]fenyl}-3-(3-fluor-5-metylfenyl)kinolin-4-yl)piperidin-3-ol;

2-235: metyl-N-(2-{4-[trans-4-amino-3-metoksypiperidin-1-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl}-4,6-difluorfenyl)karbamat;

2-236: 1-(2-{4-[trans-4-amino-3-metoksypiperidin-1-yl]-3-(3-fluor-5-metylfenyl)kinolin-6-yl}-4,6-difluorfenyl)-3-metoksyurea;

2-237: 1-{2-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-4-cyano-6-fluorfenyl}-3-metoksyurea;

2-239: 1-{3-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]-6-metylpyridin-2-yl}-3-metoksyurea;

2-240: 1-{4-[4-(4-aminopiperidin-1-yl)-3-(3-fluor-5-metylfenyl)kinolin-6-yl]fenyl}-3-metoksyurea;

2-241: 2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-6-brom-3,4-difluorfenol;

2-243: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-6-[(1E)-(metoksyimino)metyl]fenol;

2-244: 5-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-aminopyridin-3-karbonitril;

2-246: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}pyridin-2-amin;

2-247: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-metylpyridin-3-amin;

2-248: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}pyridin-2-ol;

2-250: 2-[4-(4-aminopiperidin-1-yl)-3-(3,5-difluorfenyl)kinolin-6-yl]-4-metylpyridin-3-amin;

2-251: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-3-hydroksypyridin-4-karbonitril;

2-254: 5-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-hydroksypyridin-3-karbonitril;

2-256: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-5-fluorpyridin-4-ol;

2-258: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-metylpyridin-3-ol;

2-259: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-5-fluorpyridin-2-ol;

2-261: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-3-fluorpyridin-4-karbonitril;

2-262: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-3-aminopyridin-4-karbonitril;

2-263: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}pyridin-3-ol;

2-264: N-[(3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}pyridin-2-yl)metyliden]hydroksylamin;

2-265: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-5-fluorpyridin-3-amin;

2-266: 3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-5-[(metoksyimino)metyl]pyridin-4-amin;

2-269: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-[(metoksyimino)metyl]pyridin-3-amin;

2-273: 1-(3-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}pyridin-2-yl)-3-metoksyurea;

2-275: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-klorpyridin-3-amin;

2-283: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}pyridin-3-amin;

2-284: 2-{4-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-metoksypyridin-3-amin;

2-285: 2-{4-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-6-[(metoksyimino)metyl]fenol;

2-286: 2-{4-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-6-[(metoksyimino)metyl]fenol;

2-287: 2-{4-[(4aR,8aR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-[(metoksyimino)metyl]pyridin-3-amin;

2-288: 2-{4-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-[(metoksyimino)metyl]pyridin-3-amin;

2-289: 2-{4-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-3-aminopyridin-4-karbonitril;

2-290: 2-{4-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-3-aminopyridin-4-karbonitril;

2-291: (5-{4-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-aminopyridin-3-karbonitril;

2-292: (5-{4-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-aminopyridin-3-karbonitril;

2-293: 3-{4-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}pyridin-2-amin;

2-294: 3-{4-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}pyridin-2-amin;

2-295: 2-{4-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-metylpyridin-3-amin;

2-296: 2-{4-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-metylpyridin-3-amin;

2-297: 2-{4-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-metylpyridin-3-ol;

2-298: 2-{4-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-4-metylpyridin-3-ol;

2-299: 3-{4-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-5-fluor-2-hydroksybenzonitril;

2-300: 3-{4-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-3-(3,5-difluorfenyl)kinolin-6-yl}-5-fluor-2-hydroksybenzonitril;

eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav.

11. Forbindelsen ifølge krav 1, hvori forbindelsen er:

3-1: 3-[8-(4-aminopiperidin-1-yl)-7-(3-fluor-5-metylfenyl)-1,5-naftyridin-2-yl]-5-fluorbenzamid;

3-2: 3-[8-(4-aminopiperidin-1-yl)-7-(3-fluor-5-metylfenyl)-1,5-naftyridin-2-yl]-5-fluor-2-hydroksybenzonitril;

3-3: 4-[8-(4-aminopiperidin-1-yl)-7-(3-fluor-5-metylfenyl)-1,5-naftyridin-2-yl]-6-fluor-2,3-dihydro-1H-1,3-benzodiazol-2-on;

3-4: 5-[8-(4-aminopiperidin-1-yl)-7-(3-fluor-5-metylfenyl)-1,5-naftyridin-2-yl]-2,3-dihydro-1H-1,3-benzodiazol-2-on;

3-5: 6-[8-(4-aminopiperidin-1-yl)-7-(3-fluor-5-metylfenyl)-1,5-naftyridin-2-yl]-4-fluor-2,3-dihydro-1H-1,3-benzodiazol-2-on;

3-6: 3-[8-(4-aminopiperidin-1-yl)-7-(3-klor-5-metylfenyl)-1,5-naftyridin-2-yl]-5-fluor-2-hydroksybenzonitril;

3-7: 3-[8-(4-aminopiperidin-1-yl)-7-(3-fluor-5-metylfenyl)-1,5-naftyridin-2-yl]-2-hydroksybenzonitril;

3-8: 2-[8-(4-aminopiperidin-1-yl)-7-(3-fluor-5-metylfenyl)-1,5-naftyridin-2-yl]-6-fluorfenol;

3-9: 6-[8-(4-aminopiperidin-1-yl)-7-(3,5-difluorfenyl)-1,5-naftyridin-2-yl]-4-fluor-2,3-dihydro-1H-1,3-benzodiazol-2-on;

3-10: 6-{8-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-7-(3,5-difluorfenyl)-1,5-naftyridin-2-yl}-4-fluor-2,3-dihydro-1H-1,3-benzodiazol-2-on;

3-11: 4-{8-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-7-(3-fluor-5-metylfenyl)-1,5-naftyridin-2-yl}-6-fluor-2,3-dihydro-1H-1,3-benzodiazol-2-on;

3-12: 4-{8-[trans-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-7-(3,5-difluorfenyl)-1,5-naftyridin-2-yl}-1H,2H,3H-imidazo[4,5-c]pyridin-2-on;

eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav.

12. Forbindelsen ifølge krav 1, hvori forbindelsen er:

4-1: 3-[5-(4-aminopiperidin-1-yl)-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl]-2-hydroksybenzonitril;

4-2: 3-[5-(4-aminopiperidin-1-yl)-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl]-2-hydroksybenzonitril;

4-3: 3-[5-(4-aminopiperidin-1-yl)-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl]-5-fluor-2-hydroksybenzonitril;

4-4: 3-[5-(4-aminopiperidin-1-yl)-6-(3-klor-5-metylfenyl)-1,8-naftyridin-3-yl]-2-hydroksybenzonitril;

4-5: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-6: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-7: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl}-5-fluor-2-hydroksybenzonitril;

4-8: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl}-5-fluor-2-hydroksybenzonitril;

4-9: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl}-5-fluor-2-hydroksybenzonitril;

4-10: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl}-5-fluor-2-hydroksybenzonitril;

4-11: 2-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl}-3-aminopyridin-4-karbonitril;

4-12: 2-{5-[(4aS,8aS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl}-3-aminopyridin-4-karbonitril;

4-13: 5-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl}-4-aminopyridin-3-karbonitril;

4-14: 5-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b]morfolin-6-yl]-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl}-4-aminopyridin-3-karbonitril;

4-15: 2-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl}-3-aminopyridin-4-karbonitril;

4-16: 2-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl}-3-aminopyridin-4-karbonitril;

4-17: 2-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-fluorfenyl)-1,8-naftyridin-3-yl}-3-aminopyridin-4-karbonitril;

4-18: 2-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-fluorfenyl)-1,8-naftyridin-3-yl}-3-aminopyridin-4-karbonitril;

4-19: 2-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-metylfenyl)-1,8-naftyridin-3-yl}-3-aminopyridin-4-karbonitril;

4-20: 2-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-metylfenyl)-1,8-naftyridin-3-yl}-3-aminopyridin-4-karbonitril;

4-21: 2-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl}-4-[(metoksyimino)metyl]pyridin-3-amin;

4-22: 2-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl}-4-[(metoksyimino)metyl]pyridin-3-amin;

4-23: 2-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-metylfenyl)-1,8-naftyridin-3-yl}-4-[(metoksyimino)metyl]pyridin-3-amin;

4-24: 2-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-metylfenyl)-1,8-naftyridin-3-yl}-4-[(metoksyimino)metyl]pyridin-3-amin;

4-25: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-26: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-27: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-fluorfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-28: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-fluorfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-29: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-fluor-5-metoksyfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-30: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-fluor-5-metoksyfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-31: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-metylfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-32: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-metylfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-33: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3,5-diklorfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-34: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3,5-diklorfenyl)-1,8-naftyridin-3-yl}-2-hydroksybenzonitril;

4-35: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-36: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3,5-difluorfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-37: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-38: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-fluor-5-metylfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-39: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-fluor-5-metoksyfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-40: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-fluor-5-metoksyfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-41: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-fluorfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-42: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-fluorfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-43: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-metylfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-44: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3-klor-5-metylfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-45: 3-{5-[(4αR,8αR)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3,5-diklorfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

4-46: 3-{5-[(4αS,8αS)-oktahydro-1H-pyrido[3,4-b][1,4]oksazin-6-yl]-6-(3,5-diklorfenyl)-1,8-naftyridin-3-yl}pyridin-2-amin;

eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav.

13. Forbindelsen ifølge krav 1, hvori forbindelsen har følgende struktur:



,

eller et farmasøytisk akseptabelt salt eller solvat derav.

14. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1 til 12, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav, og minst én farmasøytisk akseptabel eksipiens.

15. Farmasøytisk sammensetning omfattende en forbindelse ifølge krav 13, eller et farmasøytisk akseptabelt salt, eller solvat derav, og minst én farmasøytisk akseptabel eksipiens.

16. Den farmasøytiske sammensetningen ifølge krav 14 eller krav 15, hvori den farmasøytiske sammensetningen er i form av en tablett, en pille eller en kapsel.

17. Forbindelse ifølge et hvilket som helst av kravene 1 til 12, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav, for anvendelse som en medisin.

18. Forbindelse ifølge krav 13, eller et farmasøytisk akseptabelt salt, eller solvat derav, for anvendelse som en medisin.

19. Forbindelse ifølge et hvilket som helst av kravene 1 til 12, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav, for anvendelse i behandlingen av akromegali, en nevroendokrin svulst, en oftalmisk sykdom eller tilstand, nevropati, nefropati, en respiratorisk sykdom eller tilstand, kreft, smerte, en nevrodegenerativ sykdom eller tilstand, en inflammatorisk sykdom eller tilstand, en psykiatrisk sykdom eller tilstand, eller kombinasjoner derav.

20. Forbindelse ifølge krav 13, eller et farmasøytisk akseptabelt salt, eller solvat derav, for anvendelse i behandlingen av akromegali, en nevroendokrin svulst, en oftalmisk sykdom eller tilstand, nevropati, nefropati, en respiratorisk sykdom eller tilstand, kreft, smerte, en nevrodegenerativ sykdom eller tilstand, en inflammatorisk sykdom eller tilstand, en psykiatrisk sykdom eller tilstand, eller kombinasjoner derav.

21. Farmasøytisk sammensetning ifølge et hvilket som helst av kravene 14 til 16 for anvendelse i behandlingen av akromegali, en nevroendokrin svulst, en oftalmisk sykdom eller tilstand, nevropati, nefropati, en respiratorisk sykdom eller tilstand, kreft, smerte, en nevrodegenerativ sykdom eller tilstand, en inflammatorisk sykdom eller tilstand, en psykiatrisk sykdom eller tilstand, eller kombinasjoner derav.

22. Forbindelse ifølge et hvilket som helst av kravene 1 til 12, eller et farmasøytisk akseptabelt salt, solvat, diastereomerblanding eller individuelle enantiomerer derav, for anvendelse i behandlingen av akromegali, en nevroendokrin svulst eller kombinasjoner derav.

23. Forbindelse ifølge krav 13, eller et farmasøytisk akseptabelt salt, eller solvat derav, for anvendelse i behandlingen av akromegali, en nevroendokrin svulst eller kombinasjoner derav.

24. Farmasøytisk sammensetning ifølge et hvilket som helst av kravene 14 til 16 for anvendelse i behandlingen av akromegali, en nevroendokrin svulst eller kombinasjoner derav.